{
    "info": {
        "nct_id": "NCT03040999",
        "official_title": "A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)",
        "inclusion_criteria": "* Has a pathologically proven new diagnosis of oropharyngeal p16 positive, oropharyngeal p16 negative, or larynx/hypopharynx/oral cavity (independent of p16) squamous cell carcinoma. Participants with oral cavity tumors need to have unresectable disease. Participants with multiple synchronous tumors are not eligible for the study.\n* Has provided tissue for Programmed Cell Death Receptor Ligand 1 (PD-L1) biomarker analysis from a core or excisional biopsy. If an excisional or incisional biopsy has been performed, participants remain eligible for the study provided the residual disease meets the staging criteria required for the trial (e.g., excisional biopsy of a lymph node with residual T4 primary). Prior surgical debulking, including tonsillectomy, for the head and neck cancer under study is not allowed.\n* Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1\n* Is eligible for definitive CRT and not considered for primary surgery based on investigator decision\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days prior to receiving the first dose of study therapy\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy\n* Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy\n* Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-PD-L1, anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor or has previously participated in clinical studies with pembrolizumab\n* Has received a live vaccine within 30 days prior to the first dose of study therapy\n* Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer\n* Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study\n* Has not recovered from major surgery prior to starting study therapy\n* Has known active Hepatitis B or C\n* Has known history of Human Immunodeficiency Virus (HIV)\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment.\n* Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has had previous allogeneic tissue/solid organ transplant\n* Has active infection requiring systemic therapy\n* Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs\n* Is pregnant or breast feeding or expecting to conceive or father children throughout the study period and for up to 180 days after the last dose of study therapy",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is eligible for definitive CRT and not considered for primary surgery based on investigator decision",
            "criterions": [
                {
                    "exact_snippets": "Is eligible for definitive CRT",
                    "criterion": "eligibility for definitive chemoradiotherapy (CRT)",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not considered for primary surgery based on investigator decision",
                    "criterion": "consideration for primary surgery",
                    "requirements": [
                        {
                            "requirement_type": "consideration",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "decision authority",
                            "expected_value": "investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Female and male participants of reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use adequate contraception throughout the study period and for up to 180 days after the last dose of study therapy",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "throughout the study period",
                                "for up to 180 days after the last dose of study therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days prior to receiving the first dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 10 days prior to receiving the first dose of study therapy",
                    "criterion": "ECOG performance status assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "time before first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has provided tissue for Programmed Cell Death Receptor Ligand 1 (PD-L1) biomarker analysis from a core or excisional biopsy. If an excisional or incisional biopsy has been performed, participants remain eligible for the study provided the residual disease meets the staging criteria required for the trial (e.g., excisional biopsy of a lymph node with residual T4 primary). Prior surgical debulking, including tonsillectomy, for the head and neck cancer under study is not allowed.",
            "criterions": [
                {
                    "exact_snippets": "Has provided tissue for Programmed Cell Death Receptor Ligand 1 (PD-L1) biomarker analysis from a core or excisional biopsy",
                    "criterion": "tissue for PD-L1 biomarker analysis",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "core biopsy",
                                "excisional biopsy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If an excisional or incisional biopsy has been performed, participants remain eligible for the study provided the residual disease meets the staging criteria required for the trial",
                    "criterion": "residual disease after excisional or incisional biopsy",
                    "requirements": [
                        {
                            "requirement_type": "meets staging criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior surgical debulking, including tonsillectomy, for the head and neck cancer under study is not allowed",
                    "criterion": "prior surgical debulking for head and neck cancer under study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a pathologically proven new diagnosis of oropharyngeal p16 positive, oropharyngeal p16 negative, or larynx/hypopharynx/oral cavity (independent of p16) squamous cell carcinoma. Participants with oral cavity tumors need to have unresectable disease. Participants with multiple synchronous tumors are not eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "pathologically proven new diagnosis of oropharyngeal p16 positive, oropharyngeal p16 negative, or larynx/hypopharynx/oral cavity (independent of p16) squamous cell carcinoma",
                    "criterion": "squamous cell carcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "oropharyngeal p16 positive",
                                "oropharyngeal p16 negative",
                                "larynx",
                                "hypopharynx",
                                "oral cavity"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with oral cavity tumors need to have unresectable disease",
                    "criterion": "oral cavity tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with multiple synchronous tumors are not eligible for the study",
                    "criterion": "multiple synchronous tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1",
            "criterions": [
                {
                    "exact_snippets": "Has evaluable tumor burden (measurable and/or non-measurable tumor lesions)",
                    "criterion": "tumor burden",
                    "requirements": [
                        {
                            "requirement_type": "evaluability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed by computed tomography scan or magnetic resonance imaging",
                    "criterion": "tumor lesion assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "computed tomography scan",
                                "magnetic resonance imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "based on RECIST version 1.1",
                    "criterion": "tumor assessment criteria",
                    "requirements": [
                        {
                            "requirement_type": "assessment criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine",
                                "serum"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours prior to first dose"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has active infection requiring systemic therapy",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease that has required systemic treatment in the past 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had previous allogeneic tissue/solid organ transplant",
            "criterions": [
                {
                    "exact_snippets": "Has had previous allogeneic tissue/solid organ transplant",
                    "criterion": "previous allogeneic tissue/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy",
                    "criterion": "history of hematologic or primary solid tumor malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless in remission for at least 5 years prior to randomization",
                    "criterion": "remission duration of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "duration in remission",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known history of Human Immunodeficiency Virus (HIV)",
            "criterions": [
                {
                    "exact_snippets": "Has known history of Human Immunodeficiency Virus (HIV)",
                    "criterion": "Human Immunodeficiency Virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days prior to the first dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days prior to the first dose of study therapy",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to first dose of study therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer",
            "criterions": [
                {
                    "exact_snippets": "Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer",
                    "criterion": "primary cancer site",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "oropharynx",
                                "larynx",
                                "hypopharynx",
                                "oral cavity"
                            ]
                        },
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "nasopharyngeal",
                                "sinus",
                                "other para-nasal",
                                "other unknown primary head and neck"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Has known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "history of (non-infectious) pneumonitis that required steroids",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not recovered from major surgery prior to starting study therapy",
            "criterions": [
                {
                    "exact_snippets": "Has not recovered from major surgery prior to starting study therapy",
                    "criterion": "recovery from major surgery",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breast feeding or expecting to conceive or father children throughout the study period and for up to 180 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... throughout the study period and for up to 180 days after the last dose of study therapy",
                    "criterion": "expectation to conceive",
                    "requirements": [
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "throughout the study period and for up to 180 days after the last dose of study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children throughout the study period and for up to 180 days after the last dose of study therapy",
                    "criterion": "expectation to father children",
                    "requirements": [
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "throughout the study period and for up to 180 days after the last dose of study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1), anti-PD-L1, anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor or has previously participated in clinical studies with pembrolizumab",
            "criterions": [
                {
                    "exact_snippets": "Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1)",
                    "criterion": "prior therapy with anti-PD-1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anti-PD-L1",
                    "criterion": "prior therapy with anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anti-Programmed Cell Death Receptor Ligand 2 (PD-L2) agent",
                    "criterion": "prior therapy with anti-PD-L2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agent directed to another co-inhibitory T-cell receptor",
                    "criterion": "prior therapy with agent directed to another co-inhibitory T-cell receptor",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has previously participated in clinical studies with pembrolizumab",
                    "criterion": "prior participation in clinical studies with pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "history of participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study",
            "criterions": [
                {
                    "exact_snippets": "Has had prior systemic therapy ... for head and neck cancer under study",
                    "criterion": "prior systemic therapy for head and neck cancer under study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has had prior ... targeted therapy ... for head and neck cancer under study",
                    "criterion": "prior targeted therapy for head and neck cancer under study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has had prior ... radiotherapy treatment ... for head and neck cancer under study",
                    "criterion": "prior radiotherapy treatment for head and neck cancer under study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has had prior ... radical surgery for head and neck cancer under study",
                    "criterion": "prior radical surgery for head and neck cancer under study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs",
            "criterions": [
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to pembrolizumab",
                    "criterion": "hypersensitivity reaction to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to ... Cisplatin",
                    "criterion": "hypersensitivity reaction to Cisplatin",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to ... radiotherapy",
                    "criterion": "hypersensitivity reaction to radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to ... their analogs",
                    "criterion": "hypersensitivity reaction to analogs of pembrolizumab, Cisplatin, or radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving systemic steroid therapy ... within 7 days prior to the first dose of study therapy",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving_within_days_prior_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving ... any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy",
                    "criterion": "immunosuppressive therapy (other than systemic steroids)",
                    "requirements": [
                        {
                            "requirement_type": "receiving_within_days_prior_to_first_dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Has known active Hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "Has known active Hepatitis B",
                    "criterion": "active Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known active Hepatitis C",
                    "criterion": "active Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating ... in a study with an investigational agent",
                    "criterion": "participation in a study with an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study with an investigational agent within 4 weeks of the first dose of study therapy",
                    "criterion": "prior participation in a study with an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Is currently participating ... in a study ... using an investigational device",
                    "criterion": "participation in a study using an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study using an investigational device within 4 weeks of the first dose of study therapy",
                    "criterion": "prior participation in a study using an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}